First-in-Human Phase 1 Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors

2021 ◽  
pp. clincanres.4513.2020
Author(s):  
George D. Demetri ◽  
Jason J. Luke ◽  
Antoine Hollebecque ◽  
John Powderly ◽  
Alexander I Spira ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Phase 1 Study ◽  
Drug Conjugate ◽  
Antibody Drug

scholarly journals Phase 1/2a trial of BMS-986148, an anti-mesothelin antibody-drug conjugate, alone or in combination with nivolumab in patients with advanced solid tumors

2021 ◽  
pp. clincanres.1181.2021
Author(s):  
Sylvie Rottey ◽  
Jeffrey Clarke ◽  
Kyaw Aung ◽  
Jean-Pascal Machiels ◽  
Ben Markman ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Phase 1 ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Antibody Drug

Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 2510-2510 ◽  
Author(s):  
John H. Strickler ◽  
John J. Nemunaitis ◽  
Colin D. Weekes ◽  
Ramesh K. Ramanathan ◽  
Eric Angevin ◽  
...  
Keyword(s):  
Solid Tumors ◽  
Dose Escalation ◽  
Phase 1 ◽  
Advanced Solid Tumors ◽  
Antibody Drug Conjugate ◽  
Open Label ◽  
Drug Conjugate ◽  
Label Dose ◽  
Antibody Drug
Sign in / Sign up

Export Citation Format

Share Document